The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment

doi:10.1017/CBO9780511544873.015

14 - The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment

from Part I - Basic aspects of neurodegeneration

Published online by Cambridge University Press: 04 August 2010

M. Flint Beal ,

Anthony E. Lang and

Albert C. Ludolph

Giulio Maria Pasinetti

Show author details

M. Flint Beal: Affiliation:
Cornell University, New York
Anthony E. Lang: Affiliation:
University of Toronto
Albert C. Ludolph: Affiliation:
Universität Ulm, Germany
Giulio Maria Pasinetti: Affiliation:
Neuroinflammation Research Laboratories, Mount Sinai, School of Medicine, New York, USA

Book contents

Get access

Summary

Several epidemiological studies have demonstrated a significantly lower incidence of Alzheimer's disease in individuals who regularly consume non-steroidal anti-inflammatory drugs (NSAIDs) compared with the general population. Despite this evidence, therapeutic studies investigating NSAIDs, including inhibitors of cyclooxygenase (COX)-1 and COX-2 and steroids, do not support this hypothesis. This discrepancy might be due to the fact that the bulk of epidemiological evidence has examined the likely incidence of AD prior to the onset of clinical symptoms of the disease. This inconsistency has led to the hypothesis that NSAIDs may be optimally effective as a preventive therapy prior to the onset of clinical symptoms or in individuals at high risk for AD, such as cases with mild cognitive impairment. This review will discuss recent findings from experimental models of AD neuropathology describing novel mechanisms involved in the potential beneficial role of NSAIDs. It will then examine the importance of evidence for the potential role of inflammation in amyloidosis in the AD brain. The implications of this evidence will be considered in the context of the potential negative role of inflammation in the brain during amyloid vaccination therapy in AD trials. On the basis of this information, this review will attempt to formulate a possible scenario in which optimal NSAIDs might be tested in the most favorable clinical therapeutic conditions in order to determine whether NSAIDs can provide beneficial treatment for the clinical progression of AD dementia.

Type: Chapter
Information: Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 166 - 175

DOI: https://doi.org/10.1017/CBO9780511544873.015 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Abdel-Halim, M. S., Sjoquist, B. & Anggard, E. (1978). Inhibition of prostaglandin synthesis in rat brain. Acta Pharmacol. Toxicol.(Copenh., 43, 266–72CrossRef Google Scholar PubMed

Aisen, P. S. (1997). Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology, 43, 143–9CrossRef Google Scholar PubMed

Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K. & Thomas, R. G. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology, 54, 588–93CrossRef Google Scholar PubMed

Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D. & Grajeda, H. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 6, 916–19CrossRef Google Scholar

Baumann, K., Mandelkow, E. M., Biernat, J., Piwnica-Worms, H. & Mandelkow, E. (1993). Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett., 336, 417–24CrossRef Google Scholar PubMed

Cao, C., Matsumura, K., Yamagata, K. & Watanabe, Y. (1995). Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res., 697, 187–96CrossRef Google Scholar PubMed

DeArmond, B., Francisco, C. A., Lin, J. S., Huang, F. Y., Halladay, S. & Bartziek, R. D. (1995). Safety profile of over-the-counter naproxen sodium. Clin. Ther., 17, 587–601CrossRef Google Scholar PubMed

Ferrari, R. A., Ward, S. J., Zobre, C. M., Liew, D. K., Perrone, M. H. & Connell, M. J. (1990). Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur. J. Pharmacol., 179, 25–34CrossRef Google Scholar PubMed

Fletcher, B. S., Lim, R. W., Varnum, B. C., Kujubu, D. A., Koski, R. A. & Herschman, H. R. (1991). Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J. Biol. Chem., 266, 14511–18Google Scholar PubMed

Geczy, M., Peltier, L. & Wolbach, R. (1987). Naproxen tolerability in the elderly: a summary report. J. Rheumatol., 14, 348–54Google Scholar PubMed

Giovanni, A., Keramaris, E., Morris, E. J., Hou, S. T., O'Hare, M. & Dyson, N. (2000). E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J. Biol. Chem., 275, 11553–60CrossRef Google Scholar

Grana, X. & Reddy, E. P. (1995). Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211–19Google Scholar

Haroutunian, V., Perl, D. P., Purohit, D. P., Marin, D., Khan, K. & Lantz, M. (1998). Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol., 55, 1185–91CrossRef Google Scholar PubMed

Hebert, L. E., Scherr, P.A, Bienias, J. L., Bennett, D. A. & Evans, D. A. (2003). Alzheimer disease in the US population. Arch. Neurol., 60, 1119–22CrossRef Google Scholar PubMed

Ho, L., Pieroni, C., Winger, D., Purohit, D. P., Aisen, P. S. & Pasinetti, G. M. (1999). Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res., 57, 295–3033.0.CO;2-0>CrossRef Google Scholar PubMed

Ho, L., Purohit, D., Haroutunian, V., Luterman, J. D., Willis, F. & Naslund, J. (2001). Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol., 58, 487–92CrossRef Google Scholar PubMed

In't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., Duijn, C. M. & Stijnen, T. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 345, 1515–21CrossRef Google Scholar

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y. & Schmidt, S. D. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408, 979–82CrossRef Google Scholar

Kelley, K. A., Ho, L., Winger, D., Freire-Moar, J., Borelli, C. B. & Aisen, P. S. (1999). Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol., 155, 995–1004CrossRef Google Scholar PubMed

Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W. & Herschman, H. R. (1991). TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 266, 12866–72Google Scholar PubMed

Levi, G., Minghetti, L. & Aloisi, F. (1998). Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions. Biochimie, 80, 899–904CrossRef Google Scholar

Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. & Teter, B. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci., 20, 5709–14CrossRef Google Scholar

Luterman, J. D., Haroutunian, V., Yemul, S., Ho, L., Purohit, D. & Aisen, P. S. (2000). Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol., 57, 1153–60CrossRef Google Scholar PubMed

Mandelkow, E. M. & Mandelkow, E. (1998). Tau in Alzheimer's disease. Trends Cell Biol., 8, 425–7CrossRef Google Scholar PubMed

McGeer, P. L., Schulzer, M. & McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 47, 425–32CrossRef Google Scholar PubMed

Mirjany, M., Ho, L. & Pasinetti, G. M. (2002). Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther., 301, 494–500CrossRef Google Scholar PubMed

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. & Hardy, J. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982–5CrossRef Google Scholar

Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412–14CrossRef Google Scholar PubMed

Mukherjee, P. & Pasinetti, G. M. (2001). Complement anaphylatoxin C5a neuroprotects through mitogen activated protein kinase dependent inhibition of caspase 3. J. Neurochem., 76, 1–8Google Scholar

O'Banion, M. K., Winn, V. D. & Young, D. A. (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA, 89, 4888–92CrossRef Google Scholar PubMed

Oka, A. & Takashima, S. (1997). Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. NeuroReport, 8, 1161–4CrossRef Google Scholar PubMed

Pasinetti, G. M. (1998). Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res., 54, 1–63.0.CO;2-M>CrossRef Google Scholar PubMed

Pasinetti, G. M. & Aisen, P. S. (1998). Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 87, 319–24CrossRef Google Scholar PubMed

Pasinetti, G. M. & Pompl, P. (2002). Inflammation and Alzheimer's disease: are we well-ADAPTed?Lancet Neurol., 1, 403–4CrossRef Google Scholar

Pasinetti, G. M., Ho, L. & Pompl, P. (2002a). Amyloid immunization in Alzheimer's disease: do we promote amyloid scavenging at the cost of inflammatory degeneration?Neurobiol. Agin., 23, 665–6CrossRef Google Scholar

Pasinetti, G. M., Ho, L. & Pompl, P. (2002b). AN1792 vaccination immunotherapy in Alzheimer's disease: the case of a therapy before its time. Neurobiol Aging, 23, 683–4CrossRef Google Scholar

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol., 56, 303–8CrossRef Google Scholar PubMed

Pompl, P. N., Yemul, S., Xiang, Z.et al. (2003). Caspase gene expression in the brain as a function of the clinical progression of Alzheimer's disease. Arch. Neurol., 60, 369–76CrossRef Google Scholar

Qin, W., Ho, L., Pompl, P. N.et al. (2003). Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma secretase activity. J. Biol. Chem., 278, 50970–7CrossRef Google Scholar PubMed

Raina, A. K., Zhu, X., Rottkamp, C. A., Monteiro, M., Takeda, A. & Smith, M. A. (2000). Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J. Neurosci. Res., 61, 128–333.0.CO;2-H>CrossRef Google Scholar PubMed

Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L. & Kaszniak, A. W. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609–11CrossRef Google Scholar PubMed

Scharf, S., Mander, A., Ugoni, A., Vajda, F. & Christophidis, N. (1993). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 53, 197–201CrossRef Google Scholar

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H. & Guido, T. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–7CrossRef Google Scholar PubMed

Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev., 81, 741–66CrossRef Google Scholar PubMed

Shah, Y., Tangalos, E. G. & Petersen, R. C. (2000). Mild cognitive impairment. When is it a precursor to Alzheimer's disease?Geriatrics, 55, 62, 65–8Google Scholar PubMed

Shiff, S. J., Koutsos, M. I., Qiao, L. & Rigas, B. (1996). Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res., 222, 179–88CrossRef Google Scholar PubMed

Spielman, L., Winger, D., Ho, L., Aisen, P. S., Shohami, E. & Pasinetti, G. M. (2002). Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol.(Berl.), 103, 157–62CrossRef Google Scholar

Sramek, J. J., Veroff, A. E. & Cutler, N. R. (2001). The status of ongoing trials for mild cognitive impairment. Expert. Opin. Investig. Drug., 10, 741–52CrossRef Google Scholar PubMed

Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48, 626–32CrossRef Google Scholar PubMed

Ulvestad, E., Williams, K., Matre, R., Nyland, H., Olivier, A. & Antel, J. (1994). Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J. Neuropathol. Exp. Neurol., 53, 27–36CrossRef Google Scholar PubMed

Vane, J. R. & Botting, R. M. (1995). New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res., 44, 1–10CrossRef Google Scholar PubMed

Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A. & Vane, J. R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci., USA, 96, 7563–8CrossRef Google Scholar PubMed

Webster, S., O'Barr, S. & Rogers, J. (1994). Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J. Neurosci. Res., 39, 448–56CrossRef Google Scholar PubMed

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R. & Pietrzik, C. U. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414, 212–16CrossRef Google Scholar PubMed

Xiang, Z., Ho, L., Yemul, S.et al. (2002). Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expression, 10, 271–8CrossRef Google Scholar

Yasojima, K., Schwab, C., McGeer, E. G. & McGeer, P. L. (1999). Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 830, 226–36CrossRef Google Scholar PubMed